180 Life Sciences Corp
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
FRMM$2.82-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| (unaudited) | ||
| Assets | ||
| Current Assets: | ||
| Cash | $3,724,527 | $4,585,141 |
| Prepaid expenses and other current assets | 304,226 | 556,230 |
| Total Current Assets | 4,028,753 | 5,141,371 |
| Intangible assets, net | 7,622,041 | 7,622,041 |
| Total Assets | $11,650,794 | $12,763,412 |
| Liabilities and Stockholders’ Equity | ||
| Current Liabilities: | ||
| Accounts payable | $2,124,602 | $1,933,141 |
| Accounts payable – related parties | 897,721 | 684,181 |
| Accrued expenses | 771,083 | 739,674 |
| Loans payable - current portion | 148,391 | 147,889 |
| Total Current Liabilities | 3,941,797 | 3,504,885 |
| Loans payable - noncurrent portion | 3,425 | 6,616 |
| Total Liabilities | 3,945,222 | 3,511,501 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ Equity: | ||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized; (see designations and shares authorized for Series A, Class B, Class C and Class K preferred stock) | ||
| Class B Convertible Preferred stock liability, $0.001 par value, 0 and 1,000,000 shares authorized, issued and outstanding at March 31, 2025 and December 31, 2024, respectively | - | 100 |
| Class C Preferred Stock; 1 share authorized, 0 issued and outstanding at March 31, 2025 and December 31, 2024 | - | - |
| Class K Preferred Stock; 1 share authorized, 0 issued and outstanding at March 31, 2025 and December 31, 2024, respectively | - | - |
| Common stock, $0.0001 par value; 100,000,000 shares authorized; 5,185,780 and 3,176,999 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | 519 | 318 |
| Additional paid-in capital | 154,579,238 | 153,691,755 |
| Accumulated other comprehensive income | (2,981,609) | (2,916,918) |
| Accumulated deficit | (143,892,576) | (141,523,344) |
| Total Stockholders’ Equity | 7,705,572 | 9,251,911 |
| Total Liabilities and Stockholders’ Equity | $11,650,794 | $12,763,412 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.